Publication: A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
Issued Date
2000-11-27
Resource Type
ISSN
02699370
Other identifier(s)
2-s2.0-0033738864
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
AIDS. Vol.14, No.16 (2000), 2509-2513
Suggested Citation
Kiat Ruxrungtham, Surapol Suwanagool, Jorge A. Tavel, Mena Chuenyam, Eugene Kroon, Sasiwimol Ubolyam, Supranee Buranapraditkun, Wichai Techasathit, Yeuming Li, Sean Emery, Richard T. Davey, Lisa Fosdick, Chaiyos Kunanusont, H. Clifford Lane, Praphan Phanuphak A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. AIDS. Vol.14, No.16 (2000), 2509-2513. doi:10.1097/00002030-200011100-00013 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25960
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
Abstract
Objectives: To assess the immunological and virological effects, safety profile and feasibility of subcutaneous interleukin-2 (sclL-2) therapy in an HIV-infected Thai population. Design: Seventy-two patients with baseline CD4 cell count of ≥ 350 x 106/l and no history of opportunistic infection were randomized to receive antiretroviral therapy plus scIL-2 (scIL-2 group) or antiretroviral therapy alone (control group). scIL-2 was administered at one of three doses for at least 24 weeks. The main measure of treatment efficacy was change in CD4 cell count. Results: The time-weighted mean change in CD4 cell count from baseline to week 24 was + 252 x 106/l for the scIL-2 group compared with + 42 x 106/l for the control group (P< 0.0001). Changes in plasma HIV RNA were not significantly different between the groups over the same time period: there was a 0.83 log10 copies/ml decrease for the sclL-2 group and a 0.70 log copies/ml decrease for the control group (P = 0.362). Conclusions: This study provides the most extensive experience of sclL-2 therapy in HIV-1 infected women and Asians, and demonstrates the immunological efficacy, tolerability and feasability of sclL-2 therapy in this population. Data from this study were instrumental in guiding the selection of the sclL-2 dosing regimen for ongoing phase III trials. (C) 2000 Lippincott Williams and Wilkins.